26,365 Shares in Haemonetics Co. (NYSE:HAE) Bought by LMR Partners LLP

LMR Partners LLP acquired a new stake in shares of Haemonetics Co. (NYSE:HAE - Free Report) in the fourth quarter, according to its most recent 13F filing with the Securities and Exchange Commission. The firm acquired 26,365 shares of the medical instruments supplier's stock, valued at approximately $2,059,000. LMR Partners LLP owned approximately 0.05% of Haemonetics as of its most recent filing with the Securities and Exchange Commission.

Other institutional investors and hedge funds have also bought and sold shares of the company. Janney Montgomery Scott LLC bought a new stake in shares of Haemonetics in the fourth quarter worth approximately $402,000. KBC Group NV grew its stake in shares of Haemonetics by 54.6% in the fourth quarter. KBC Group NV now owns 2,016 shares of the medical instruments supplier's stock worth $157,000 after acquiring an additional 712 shares during the period. Pacer Advisors Inc. grew its stake in shares of Haemonetics by 36.1% in the fourth quarter. Pacer Advisors Inc. now owns 10,104 shares of the medical instruments supplier's stock worth $789,000 after acquiring an additional 2,680 shares during the period. Boston Trust Walden Corp grew its stake in shares of Haemonetics by 13.1% in the fourth quarter. Boston Trust Walden Corp now owns 915,722 shares of the medical instruments supplier's stock worth $71,500,000 after acquiring an additional 106,114 shares during the period. Finally, Empowered Funds LLC bought a new stake in shares of Haemonetics in the fourth quarter worth approximately $319,000. 99.67% of the stock is currently owned by institutional investors.

Haemonetics Price Performance

NYSE:HAE traded up $1.03 during trading hours on Friday, hitting $70.41. 369,783 shares of the stock traded hands, compared to its average volume of 698,510. The company has a quick ratio of 2.55, a current ratio of 3.97 and a debt-to-equity ratio of 1.35. Haemonetics Co. has a 1 year low of $55.30 and a 1 year high of $95.82. The company has a market cap of $3.54 billion, a price-to-earnings ratio of 27.72, a price-to-earnings-growth ratio of 1.11 and a beta of 0.32. The stock has a 50 day moving average price of $62.92 and a 200 day moving average price of $71.22.

Haemonetics (NYSE:HAE - Get Free Report) last issued its quarterly earnings results on Thursday, May 8th. The medical instruments supplier reported $1.24 earnings per share for the quarter, beating the consensus estimate of $1.22 by $0.02. Haemonetics had a net margin of 9.47% and a return on equity of 23.66%. The business had revenue of $330.60 million for the quarter, compared to the consensus estimate of $329.38 million. During the same quarter in the previous year, the firm earned $0.90 earnings per share. The company's revenue for the quarter was down 3.5% on a year-over-year basis. Sell-side analysts forecast that Haemonetics Co. will post 4.55 EPS for the current fiscal year.

Analysts Set New Price Targets

A number of analysts have recently commented on HAE shares. JMP Securities reduced their price target on shares of Haemonetics from $125.00 to $100.00 and set a "market outperform" rating for the company in a research note on Friday, February 7th. Bank of America downgraded shares of Haemonetics from a "neutral" rating to an "underperform" rating and dropped their price objective for the stock from $95.00 to $68.00 in a report on Friday, February 7th. Barrington Research dropped their price objective on shares of Haemonetics from $108.00 to $95.00 and set an "outperform" rating on the stock in a report on Friday, February 7th. StockNews.com downgraded shares of Haemonetics from a "buy" rating to a "hold" rating in a report on Tuesday. Finally, Raymond James reissued a "strong-buy" rating and issued a $105.00 price objective (down previously from $115.00) on shares of Haemonetics in a report on Friday, May 9th. One investment analyst has rated the stock with a sell rating, two have assigned a hold rating, six have given a buy rating and one has assigned a strong buy rating to the stock. According to data from MarketBeat.com, the stock currently has an average rating of "Moderate Buy" and a consensus price target of $97.89.

Haemonetics Profile

Haemonetics Corporation, a healthcare company, provides suite of medical products and solutions in the United States and internationally. The company offers automated plasma collection systems, donor management software, and supporting software solutions including NexSys PCS and PCS2 plasmapheresis equipment and related disposables and solutions, as well as integrated information technology platforms for plasma customers to manage their donors, operations, and supply chain; and NexLynk DMS donor management system and Donor360 app.